SAN DIEGO, Dec. 17, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced today the expansion of its senior leadership team in support of the planned launch of Zohydro™ ER (hydrocodone bitartrate) extended-release capsules in March 2014. This includes the appointment of a Chief Medical Officer, Vice President of Medical and Scientific Affairs, and Executive Director of Medical Affairs, effective immediately.
Help employers find you! Check out all the jobs and post your resume.